A Phase I first-in-human clinical trial to evaluate the safety, pharmacokinetics, and antiviral activity of the broadly neutralizing antibody BNT351 in adults living without and with HIV.
PROPEL – Pioneering Research to Optimize Pre-exposure Prophylaxis (PrEP) Expansion with Lenacapavir (LEN)
Español 
English 
العربية 
Polski 
简体中文